Evidence map›Paper›PMID 39608213›Full record

ArticleTranslational oncology2025

Immunogenic clearance combined with PD-1 blockade elicits antitumor effect by promoting the recruitment and expansion of the effector memory-like CD8

Seong A Kim, Seohyun Kim, Yeonsun Hong, Yoonjeong Choi, Yeji Lee, Minsu Kwon, Seung-Yoon Park, Cherlhyun Jeong, Gi-Hoon Nam, Rafael T Han and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Seong A KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Seohyun KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Department of Research and Development, ShiftBio, Seoul 02751, Republic of Korea.
Yeonsun HongKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Yoonjeong ChoiKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Department of Research and Development, ShiftBio, Seoul 02751, Republic of Korea.
Yeji LeeKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
Minsu KwonDepartment of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Seung-Yoon ParkDepartment of Biochemistry, School of Medicine, Dongguk University, Gyeongju 38066, Republic of Korea.
Cherlhyun JeongBiomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea; Department of Biological Chemistry, Korea University of Science and Technology, KIST Campus, 02841, Republic of Korea.
Gi-Hoon NamDepartment of Research and Development, ShiftBio, Seoul 02751, Republic of Korea; Department of Biochemistry and Molecular Biology, Korea University College of Medicine, Seoul 02841, Republic of Korea. Electronic address: maxcrates@korea.ac.kr.
Rafael T HanBiomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea; KHU-KIST Department of Converging Science and Technology, Kyung Hee University, Seoul 02447, Republic of Korea. Electronic address: rt.han@kist.re.kr.
In-San KimKU-KIST Graduate School of Converging Science and Technology, Korea University, Seoul 02841, Republic of Korea; Biomedical Research Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea. Electronic address: iskim14@kist.re.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibition shows promise for cancer treatment, but only a minority of patients respond. Combination strategies have been explored to overcome this resistance. Combining immunogenic clearance using immunogenic cell death inducers with a rho kinase inhibitor enhances phagocytosis of immunogenically dying cancer cells by antigen-presenting cells, stimulating tumor-specific immune responses by activating CD8

Indexed as

CD8(+) T cellCombination therapyImmune checkpoint inhibitorImmunotherapySingle cell RNA sequencing

Identifiers

PMID39608213
PMCPMC11635775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.